A
Alcista
Alcista · 25%SNY
$56.80
Precio del escenario
$40.610
+0.321 (+0.79%)Al cierre
Loading chart…
- Máximo
- 40.610
- Apertura
- 40.360
- Precio medio ponderado por volumen
- 40.46
- Volumen
- 4.63M
- Capitalización
- 120.30B
- Mínimo
- 40.160
- Importe
- 187.41M
- EV/EBITDA, TTM
- 6.90
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Análisis de IA of Sanofi SA (SNY)
MantenerSanofi SA is currently a hold. The stock is trading at $40.07, which is significantly below the analyst price target of EUR 80, indicating potential upside. However, the RSI is at 37.151, suggesting it is in a bearish trend, and the forward P/E ratio of 8.5911 indicates it is undervalued compared to its earnings potential. The main risk is the negative sentiment surrounding Dupixent's patent cliff, which could impact future revenues.
Recomendaciones de analistas (3)
+95.42% de potencial alcista
Comprar
2 Comprar
1 Mantener
0 Vender
Actual: 40.61
Mínimo
57.00
Promedio
79.36
Máximo
119.07
HSBC
Comprar
—
2026-09-10
HSBC
2026-09-10
Precio objetivo
—
Comprar
RBC Capital
Sector Perform
—
2026-09-08
RBC Capital
2026-09-08
Precio objetivo
—
Sector Perform
Morgan Stanley
Equal Weight
—
2026-08-11
Morgan Stanley
2026-08-11
Precio objetivo
—
Equal Weight
Morgan Stanley
Equal Weight
$49
2026-07-08
Morgan Stanley
2026-07-08
Precio objetivo
$49
Equal Weight
BofA
Neutral
—
2026-06-22
BofA
2026-06-22
Precio objetivo
—
Neutral
Métricas de valoración
El PER previsto actual de Sanofi SA (SNY) es 8.59, frente a su media de 5 años de 9.57.
Escenarios de precio de Alphio AI para SNY
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con SNY en cartera
Cronología de eventos
Noticias
8.510-15stocktwitsRecursion to Receive Over $300 Million in Milestone Payments from Sanofi Collaboration
8.510-14NewsfilterMindWalk Strengthens Development Leadership, Advances Preclinical Research
8.510-03stocktwitsNovartis Partners with Abogen in $7.8 Billion Deal
8.510-02PRnewswireKarl-Anthony Towns Partners with Sanofi to Promote COVID-19 Vaccination
- 8.510-02Newsfilter
Karl-Anthony Towns Advocates for COVID-19 Vaccination Awareness
Preguntas frecuentes sobre SNY, respondidas por Alphio AI
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Sanofi SA is currently a hold. The stock is trading at $40.07, which is significantly below the analyst price target of EUR 80, indicating potential upside. However, the RSI is at 37.151, suggesting it is in a bearish trend, and the forward P/E ratio of 8.5911 indicates it is undervalued compared to its earnings potential. The main risk is the negative sentiment surrounding Dupixent's patent cliff, which could impact future revenues.
3 analysts cover SNY: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 79.36.
Comunidad
Más ↗
$RXRX stock is heading for its best day in over a year. What's driving the rally today? $RXRX $SNY
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.